Nicotinamide Reduces Skin Cancer Risk – Study Finds

Nicotinamide Shows Promise for Skin Cancer Prevention, But Timing Matters: A Deep Dive into a Recent Study

This article discusses a recent study published in JAMA Dermatology investigating the real-world impact of nicotinamide (vitamin B3) on nonmelanoma skin cancer risk. here’s a breakdown of the key findings and context:

Key Takeaways:

* Nicotinamide is associated with a decreased risk of new keratinocyte skin cancers overall. This includes cutaneous squamous cell carcinoma (CSCC), but not basal cell carcinoma (BCC).
* Timing is crucial: ⁢The protective effect is strongest when nicotinamide supplementation is started after a patient’s⁣ first skin cancer diagnosis (56% reduction in risk).
* diminishing Returns: The benefit weakens with each subsequent skin cancer diagnosis, becoming‍ insignificant after the ⁢seventh.
* Real-World Data: This study provides valuable real-world evidence, ⁢complementing previous randomized controlled trials ⁢(RCTs).

Background & Why This Matters:

* rising Skin Cancer Rates: Nonmelanoma skin cancers⁣ (BCC⁣ and CSCC) are the most common cancers globally, and their prevalence is increasing.
* High Recurrence Risk: Individuals who have had one skin cancer are at substantially higher risk of developing ‍another.
* Nicotinamide as a⁢ Potential Preventative: A 2015 RCT showed promising results with nicotinamide reducing new skin cancer rates in high-risk patients. Though, a subsequent RCT in transplant recipients didn’t show the same benefit.
* Lack of ⁢Large-Scale Data: Despite initial positive findings, large-scale, real-world data⁢ on nicotinamide’s effectiveness was lacking.

About the Study:

* Large Cohort: Researchers analyzed electronic health records from over 33,000 U.S. veterans.
* Retrospective Analysis: This was an observational study, meaning it ⁤identifies ⁢associations, not proven cause-and-effect relationships.
* Comparison Groups: 12,287 veterans⁤ who were prescribed oral nicotinamide were compared to 21,479 similar veterans who didn’t take the supplement.
* Propensity Score Matching (PSM): A statistical method used to ensure the comparison groups were as ⁢similar as possible,accounting for factors like age,sex,race,medical history,and prior skin cancer diagnoses.
* Data Source: U.S. Veterans ⁤Affairs (VA) Corporate Data Warehouse (CDW) – a large repository of electronic health records (EHRs).
* Outcome⁤ Measurement: Time to development of a new, procedurally treated skin cancer.

Study Participants:

* Mean age: 77.2 years
* 2.0% women
* 94.9% white

In essence, this study reinforces the potential of nicotinamide as a chemopreventive agent for skin cancer, but highlights the importance of initiating supplementation early in a patient’s history of skin cancer development. It suggests that the benefit is greatest for those who are newly diagnosed and ‍haven’t experienced multiple recurrences.